亚宝药业
(600351)
| 流通市值：48.02亿 | | | 总市值：48.02亿 |
| 流通股本：6.92亿 | | | 总股本：6.92亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,663,165,185.78 | 1,144,946,503.15 | 572,022,344.93 | 2,240,063,505.22 |
| 营业收入 | 1,663,165,185.78 | 1,144,946,503.15 | 572,022,344.93 | 2,240,063,505.22 |
| 二、营业总成本 | 1,338,448,847.99 | 916,155,852.99 | 446,340,355.85 | 1,910,000,308.4 |
| 营业成本 | 757,415,734.51 | 526,844,821.93 | 267,453,357.65 | 1,063,788,746.1 |
| 税金及附加 | 24,826,002.15 | 17,249,358.45 | 8,204,767.23 | 34,260,998.62 |
| 销售费用 | 316,993,178.4 | 217,146,896.42 | 103,576,284.48 | 451,801,241.78 |
| 管理费用 | 169,343,246.15 | 112,269,529.47 | 49,118,006.45 | 246,054,656.52 |
| 研发费用 | 71,670,261.36 | 43,415,654.75 | 18,348,350.61 | 117,270,588.18 |
| 财务费用 | -1,799,574.58 | -770,408.03 | -360,410.57 | -3,175,922.8 |
| 其中:利息费用 | 528,291.46 | 414,068.3 | 187,909.54 | 1,455,727.72 |
| 其中:利息收入 | 2,681,327.4 | 1,422,289.43 | 705,047.15 | 5,013,992.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -20,160,928.3 | -16,308,139.15 | -14,061,111.77 | 19,004,345.09 |
| 加:投资收益 | 2,802,699.48 | 2,349,415.29 | 903,958.83 | 74,038,738.49 |
| 资产处置收益 | 1,766,847.61 | 1,530,831.53 | - | 182,987.15 |
| 资产减值损失(新) | -3,479,749.12 | -424,908.11 | 1,374,023.15 | -83,579,791.24 |
| 信用减值损失(新) | -1,124,499.29 | -2,630,647.25 | 303,318.85 | 8,302,156.71 |
| 其他收益 | 20,567,036.38 | 17,961,243.67 | 10,173,386.66 | 22,827,144.49 |
| 四、营业利润 | 325,087,744.55 | 231,268,446.14 | 124,375,564.8 | 370,838,777.51 |
| 加:营业外收入 | 3,385,976.82 | 1,463,936 | 433,036.01 | 7,120,275.25 |
| 减:营业外支出 | 5,600,480.7 | 3,418,828.78 | 56,021.49 | 3,501,373.58 |
| 五、利润总额 | 322,873,240.67 | 229,313,553.36 | 124,752,579.32 | 374,457,679.18 |
| 减:所得税费用 | 66,127,242.62 | 50,082,393.45 | 17,779,565.1 | 74,558,401.51 |
| 六、净利润 | 256,745,998.05 | 179,231,159.91 | 106,973,014.22 | 299,899,277.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 256,745,998.05 | 179,231,159.91 | 106,973,014.22 | 299,899,277.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 256,596,371.96 | 177,596,487.26 | 106,662,285.31 | 320,013,385.64 |
| 少数股东损益 | 149,626.09 | 1,634,672.65 | 310,728.91 | -20,114,107.97 |
| 扣除非经常损益后的净利润 | 257,611,488.98 | 179,283,467.83 | 111,645,838.17 | 231,571,401.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.37 | 0.26 | 0.15 | 0.46 |
| 八、其他综合收益 | 1,363,821.68 | 1,363,821.68 | - | -3,161,788.86 |
| 归属于母公司股东的其他综合收益 | 1,363,821.68 | 1,363,821.68 | - | -3,161,788.86 |
| 九、综合收益总额 | 258,109,819.73 | 180,594,981.59 | 106,973,014.22 | 296,737,488.81 |
| 归属于母公司股东的综合收益总额 | 257,960,193.64 | 178,960,308.94 | 106,662,285.31 | 316,851,596.78 |
| 归属于少数股东的综合收益总额 | 149,626.09 | 1,634,672.65 | 310,728.91 | -20,114,107.97 |
| 公告日期 | 2026-10-28 | 2026-08-01 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |